Comparative Evaluation of Urinary PCA3 and TMPRSS2: ERG Scores and Serum PHI in Predicting Prostate Cancer Aggressiveness

International Journal of Molecular Sciences

Lucile Tallon²  Devillier Luangphakdy²  Alain Ruffion³  Marc Colombel³  Marian Devonec³  Denis Champetier¹  Philippe Paparel³  Myriam Decaussin-Petrucci³  Paul Perrin³ 

[1] Department of Urology, University Hospital of Lyon Sud, Hospices Civils of Lyon, Chemin du Grand Revoyet, 69495 Pierre Bénite, France; E-Mail:;Medical Unit of Molecular Oncology and Transfer, Department of Biochemistry and Molecular Biology, University Hospital of Lyon Sud, Hospices Civils of Lyon, Chemin du Grand Revoyet, 69495 Pierre Bénite, France; E-Mails:;Department of Medicine and Pharmacy, Faculty of Lyon 1 University, 8 Avenue Rockefeller, 69373 Lyon, France; E-Mails:

关键词: urine biomarker;    prostate cancer;    PCA3;    TMPRSS2-ERG gene fusion;    PHI;    radical prostatectomy;    aggressiveness;   

DOI  :  10.3390/ijms150813299

来源: mdpi

【 摘 要 】

It has been suggested that urinary PCA3 and TMPRSS2:ERG fusion tests and serum PHI correlate to cancer aggressiveness-related pathological criteria at prostatectomy. To evaluate and compare their ability in predicting prostate cancer aggressiveness, PHI and urinary PCA3 and TMPRSS2:ERG (T2) scores were assessed in 154 patients who underwent radical prostatectomy for biopsy-proven prostate cancer. Univariate and multivariate analyses using logistic regression and decision curve analyses were performed. All three markers were predictors of a tumor volume ≥0.5 mL. Only PHI predicted Gleason score ≥7. T2 score and PHI were both independent predictors of extracapsular extension (≥pT3), while multifocality was only predicted by PCA3 score. Moreover, when compared to a base model (age, digital rectal examination, serum PSA, and Gleason sum at biopsy), the addition of both PCA3 score and PHI to the base model induced a significant increase (+12%) when predicting tumor volume >0.5 mL. PHI and urinary PCA3 and T2 scores can be considered as complementary predictors of cancer aggressiveness at prostatectomy.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.